A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

Foluso O. Ademuyiwa, Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, E. Claire Dees, Cesar A. Santa-Maria, Roisin M. Connolly, Jeremy Force, Alvaro Moreno-Aspitia, John M. Herndon, Madelyn Carmody, Sherri R. Davies, Sarah Larson, Kathleen L. Pfaff, Stephanie M. Jones, Jason L. WeiratherAnita Giobbie-Hurder, Scott J. Rodig, Zheng Liu, Ian S. Hagemann, Elad Sharon, William E. Gillanders

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013'. Together they form a unique fingerprint.

Medicine & Life Sciences